48 completed, 19 recruiting, 9 active not recruiting, 9 unknown. 101 Phase 2, 20 Phase 1.
Follow BeiGene: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 Sonrotoclax, Azacitidine (AZA) - Myelodysplastic Syndromes, High Risk | Phase 1 / Phase 2 | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 60 | 2026-10-15 | 2026-10-21 |
| Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia zanubrutinib + BGB-11417 - Waldenstrom Macroglobulinemia | Phase 2 | Not yet recruiting | French Innovative Leukemia Organisation | 102 | 2025-12-01 | 2025-11-26 |
| A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC Tislelizumab + Anlotinib - SCLC, Limited Stage | Phase 2 | Recruiting | Yantai Yuhuangding Hospital | 20 | 2025-11-04 | 2026-09-11 |
| Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC Zanidatamab, Tislelizumab, Cisplatin - Muscle Invasive Bladder Cancer (MIBC) | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 25 | 2025-10-25 | 2025-12-22 |
| Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Cisplatin - Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer | Phase 2 | Recruiting | Ming-Yu Lien | 45 | 2025-09-26 | 2026-02-27 |
| A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy Tislelizumab, Fruquintinib - Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 15 | 2025-09-18 | 2026-08-12 |
| A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis BGB-45035, Placebo - Rheumatoid Arthritis | Phase 2 | Terminated | BeiGene | 49 | 2025-08-21 | 2026-05-28 |
| Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma Tislelizumab, Paclitaxel, Cisplatin - ESCC, Total Neoadjuvant Treatment | Phase 2 | Recruiting | National Taiwan University Hospital | 50 | 2025-07-23 | 2026-01-27 |
| Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer Tislelizumab & Fruquintinib - Metastatic Colorectal Cancer, mCRC | Phase 2 | Withdrawn | Sun Yat-sen University | 2025-07-01 | 2024-07-09 | |
| Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL Glofitamab, Polatuzumab Vedotin, Zanubrutinib - Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 38 | 2025-06-20 | 2026-10-16 |
| BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma Bendamustine, Rituximab, Cytarabine - Mantle Cell Lymphoma, Lymphoma | Phase 2 | Recruiting | Christine Ryan | 60 | 2025-04-22 | 2026-02-20 |
| Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma Obinutuzumab, Glofitamab, Venetoclax Oral Product - Lymphoma, Mantle-Cell | Phase 2 | Recruiting | The Lymphoma Academic Research Organisation | 100 | 2025-02-21 | 2026-07-10 |
| A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis HIPEC, SOX, Immune Checkpoint Inhibitors - Gastric Cancer | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 34 | 2025-02-15 | 2025-04-11 |
| Epco, Zanu, Ritux for R/R FL or MZL Zanubrutinib, Rituximab, Epcoritamab - Follicular Lymphoma, Lymphoma | Phase 2 | Recruiting | Reid Merryman, MD | 71 | 2025-01-21 | 2026-09-25 |
| Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia sonrotoclax, idarubicin/daunorubicin, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Shanghai Jiao Tong University School of Medicine | 47 | 2024-10-30 | 2026-04-30 |
| A Clinical Trial Evaluating the Efficacy and Safety of Disitamab Vedotin Plus Tislelizumab Combined with Re-TURBT in the Treatment of HER-2-high Expression(2+-3+) Non-muscle Invasive Bladder Cancer At High-risk and Very High-risk. Distitamab Vedotin in combination with Tislelizumab - NMIBC | Phase 2 | Not yet recruiting | Fujian Medical University Union Hospital | 40 | 2024-10-01 | 2024-10-10 |
| Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC Trametinib, Anlotinib, Tislelizumab - KRAS Mutation-Related Tumors, Advanced Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Chest Hospital | 60 | 2024-07-01 | 2024-06-13 |
| Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma Zanubrutinib, Rituximab - Mantle Cell Lymphoma | Phase 2 | Recruiting | University College, London | 50 | 2024-05-17 | 2025-04-16 |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas Pemetrexed, Zanubrutinib, Autologous Stem Cell Transplant (ASCT) - Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma | Phase 2 | Recruiting | Baptist Health South Florida | 15 | 2024-04-25 | 2026-03-03 |
| Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related Polyneuropathy Zanubrutinib Oral Product - Monoclonal Gammopathy of Uncertain Significance | Phase 2 | Active not recruiting | UMC Utrecht | 35 | 2024-03-01 | 2026-05-08 |
Showing 20 of 101. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (7) · Lymphoma, Large B-Cell, Diffuse (7) · Lymphoma, Mantle-Cell (7) · Colorectal Neoplasms (6) · Lymphoma, B-Cell, Marginal Zone (6) · Stomach Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Esophageal Squamous Cell Carcinoma (5) · Lymphoma, Follicular (5) · Lymphoma (4) · Neoplasms (4) · Recurrence (4) · Waldenstrom Macroglobulinemia (4) · Carcinoma, Hepatocellular (3) · Esophageal Neoplasms (3)
tislelizumab (58) · zanubrutinib (24) · Cisplatin (9) · Paclitaxel (8) · pamiparib (7) · Carboplatin (6) · Pemetrexed (6) · Docetaxel (5) · Rituximab (5) · sitravatinib (5) · HMPL-013 (4) · Capecitabine (3) · Chemoradiotherapy (3) · Fluorouracil (3) · Gemcitabine (3)
China (61) · United States (31) · South Korea (18) · Australia (13) · France (13) · Spain (12) · Taiwan (12) · Italy (9) · United Kingdom (8) · Canada (5) · Thailand (5) · New Zealand (4) · Poland (4) · Brazil (3) · Czechia (3)
Alison Freimund (1) · Arvind Dasari, MD (1) · Baohui Han, MD, PhD (1) · Brian Shuch, MD (1) · Christine Ryan, MD (1) · Cynthia Sirard, MD (1) · David Schiff, MD (1) · Do-Youn Oh, M.D., PhD. (1) · Herve Ghesguieres (1) · Inhye E Ahn, MD (1) · Jeff Goh, MBBS, FRACP (1)
PMID 38502198, PMID 38775302, PMID 34152395, PMID 35900694, PMID 36879284, PMID 22919026, PMID 26770954, PMID 28034070, PMID 28188133, PMID 28486951, PMID 28879531, PMID 28911074, PMID 29386072, PMID 31520078, PMID 32393328, PMID 32461234, PMID 32561664, PMID 33047430, PMID 33332484, PMID 33827139, PMID 34473343, PMID 34702811, PMID 34716199, PMID 35303070, PMID 35390135, PMID 36400069, PMID 36797356, PMID 36799536, PMID 36820098, PMID 36922805, PMID 37276067, PMID 37276871, PMID 37506346, PMID 37682792, PMID 37699634, PMID 38650037, PMID 39114870, PMID 39376156, PMID 39432867, PMID 39563886, PMID 39624833, PMID 39762418, PMID 39906744, PMID 39978682, PMID 40008672, PMID 40334067, PMID 40341124, PMID 40411966, PMID 40812353, PMID 41202501
2017 (4), 2018 (3), 2023 (2), 2016 (1), 2019 (1), U10CA180888 (1), UM1CA137443 (1)